Testing a new immune cell therapy for hard-to-treat blood cancer

This trial is testing a new treatment called BCMA-targeted prime CAR-T cell therapy for people with multiple myeloma (a blood cancer) that hasn't responded well to standard treatments. Researchers have engineered immune cells to recognize and attack cancer cells, then infuse them back into your body. The study will measure whether this treatment is safe and whether it helps control the cancer.

Multiple myeloma can become resistant to standard chemotherapy and other treatments, leaving patients with few options. This medication targets a specific marker found on myeloma cancer cells, potentially offering a new path for people whose disease has come back or stopped responding to other therapies.